Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
暂无分享,去创建一个
Hidehiko Takahashi | K. Matsuoka | M. Higuchi | S. Nakajima | R. Tarumi | K. Tagai | K. Kawamura | K. Takahata | C. Seki | Yasuharu Yamamoto | Y. Takado | M. Kubota | S. Kurose | H. Shiwaku | Hisaomi Suzuki | Yasunori Sano | Ming-Rong Zhang | Hiroki Shiwaku
[1] T. Suhara,et al. Relationship between regional gray matter volumes and dopamine D2 receptor and transporter in living human brains , 2021, Human brain mapping.
[2] Steven H. Liang,et al. Synthesis and preliminary studies of 11C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2 , 2020, Theranostics.
[3] F. Schlagenhauf,et al. Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies , 2020, Biological Psychiatry.
[4] Zizhong Li,et al. Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development , 2019, Medicinal research reviews.
[5] J. Near,et al. Validation of in vivo MRS measures of metabolite concentrations in the human brain , 2019, NMR in biomedicine.
[6] Anissa Abi-Dargham,et al. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms , 2019, Trends in Neurosciences.
[7] G. Boscutti,et al. PET Radioligands for imaging of the PDE10A in human: current status , 2019, Neuroscience Letters.
[8] A. Egerton,et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study , 2018, The lancet. Psychiatry.
[9] Bernhard Landwehrmeyer,et al. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect , 2017, NeuroImage.
[10] René S. Kahn,et al. 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings , 2017, Biological Psychiatry.
[11] M. Lubberink,et al. Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study , 2017, Translational Psychiatry.
[12] Cornelius Weiller,et al. A Meta‐analysis on the neural basis of planning: Activation likelihood estimation of functional brain imaging results in the Tower of London task , 2017, Human brain mapping.
[13] G. Bormans,et al. Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission , 2016, EJNMMI Radiopharmacy and Chemistry.
[14] Suzanne N. Haber,et al. Corticostriatal circuitry , 2016, Dialogues in clinical neuroscience.
[15] S. Kapur,et al. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. , 2016, The American journal of psychiatry.
[16] Y. Iwata,et al. The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[17] Ashley D Harris,et al. Tissue correction for GABA‐edited MRS: Considerations of voxel composition, tissue segmentation, and tissue relaxations , 2015, Journal of magnetic resonance imaging : JMRI.
[18] R. Buchert,et al. Prefrontal and Striatal Glutamate Differently Relate to Striatal Dopamine: Potential Regulatory Mechanisms of Striatal Presynaptic Dopamine Function? , 2015, The Journal of Neuroscience.
[19] D. Jennings,et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. , 2014, JAMA neurology.
[20] Olivier Barret,et al. In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654 , 2014, The Journal of Nuclear Medicine.
[21] Timothy Edward John Behrens,et al. Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. , 2014, Cerebral cortex.
[22] S. Kapur,et al. Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [11C]MP-10 PET rodent imaging study with ex vivo confirmation , 2014, Translational Psychiatry.
[23] R. Murray,et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study , 2011, Molecular Psychiatry.
[24] M. D’Esposito,et al. Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control , 2011, Biological Psychiatry.
[25] A. Nishi,et al. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. , 2010, Journal of pharmacological sciences.
[26] T. Comery,et al. Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia , 2009, Journal of Pharmacology and Experimental Therapeutics.
[27] R. D. Williams,et al. Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia , 2008, Journal of Pharmacology and Experimental Therapeutics.
[28] R. Shigemoto,et al. Increased social interaction in mice deficient of the striatal medium spiny neuron‐specific phosphodiesterase 10A2 , 2008, Journal of neurochemistry.
[29] J. O'Donnell,et al. Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum , 2008, Neuropharmacology.
[30] R. Keefe,et al. Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version , 2007, Psychiatry and clinical neurosciences.
[31] Daniel Morton,et al. Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[32] J. Beavo,et al. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.
[33] Paul M. Grasby,et al. A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition , 2005, NeuroImage.
[34] Philip D. Harvey,et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.
[35] S. Haber. The primate basal ganglia: parallel and integrative networks , 2003, Journal of Chemical Neuroanatomy.
[36] A. Dale,et al. Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.
[37] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[38] B. Puri,et al. Recent developments in neurochemical imaging in schizophrenia: an update. , 2013, Current medicinal chemistry.
[39] D. Lewis,et al. Neuroplasticity of Neocortical Circuits in Schizophrenia , 2008, Neuropsychopharmacology.
[40] Peter Redgrave,et al. Basal Ganglia , 2020, Encyclopedia of Autism Spectrum Disorders.
[41] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.